Trabectedin is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. It is approved in close to 80 countries in North America, Europe, South America and Asia for the treatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian cancer in combination with DOXIL®/CAELYX® (doxorubicin HCl liposome injection) in the European Union.
Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It It specifically binds to eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death). Plitidepsin has been approved by TGA in Australia for the treatment of multiple myeloma in combination with dexamethasone for patients that relapse after three lines of treatment, including proteasome inhibitors or immunomodulators.
Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being or has been investigated in various types of solid tumors, as well as being in a Phase III study for small cell lung cancer currently.
PM184 is a marine-derive drug found in a sponge called Lithoplocamia lithistoides. This drug candidate is a microtubule inhibitor that targets a protein called tubulin in a novel way. It blocks cancer growth by impairing cell division of tumor cells through the inhibition of a crucial process called mitosis. It is currently being investigated in a Phase II trial for hormone-receptor positive, HER2-negative locally advanced and/or metastatic breast cancer and in studies in various solid tumors and in other Phase II solid tumor trials.
Clinical studies with PM184 in clinicaltrial.gov
PM14 is a synthetic compound under clinical investigation. It is a specific inhi-bitor of oncogenic transcription, which has demonstrated encouraging pre-clinical activity in several cancer models. Many tumors are addicted to specific oncogenic transcription programs, this addiction constituting a distinctive target that can be exploited for the treatment of patients.